[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@Wolverine0911 Wolverine
Wolverine posts on X about $abvx, sanofi, ceo, acquisition the most. They currently have XXX followers and X posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Week XXXXX +2,806%
- X Month XXXXX -XX%
- X Months XXXXXX +1,813%
- X Year XXXXXX +218%
Mentions: X #
- X Week X +50%
- X Month XX -XX%
- X Months XXX +570%
- X Year XXX +23%
Followers: XXX #
- X Week XXX +0.42%
- X Month XXX +0.85%
- X Months XXX +36%
- X Year XXX +92%
CreatorRank: XXXXXXXXX #
Social Influence
Social category influence stocks XXXXX% finance XXXXX%
Social topic influence $abvx #41, sanofi #33, ceo 33.33%, acquisition 16.67%, loaded XXXXX%
Top accounts mentioned or mentioned by @taintslapp12283
Top assets mentioned Sanofi (SNY)
Top Social Posts
Top posts by engagements in the last XX hours
"$ABVX Abivax's CEO Marc de Garidel (ex-UCB) has orchestrated "smooth" billion-dollar exits before (e.g. UCB's asset sales). Per a recent podcast they organize auctions to maximize bids by teasing data snippets and pitting suitors (Sanofi Merck Pfizer Bristol Myers Squibb AstraZeneca) against each other. Rumors peaked November XX 2025 with AstraZeneca flagged as a bidder via Betaville alerts spiking shares 11%. Tactics include phased diligence: initial bids in Q4 2025 final rounds post-earnings (Dec XX 2025) announcement pre-major catalysts to avoid dilution"
X Link 2025-12-06T23:14Z XXX followers, XXX engagements
"$ABVX Abivax's CEO Marc de Garidel (ex-UCB) has orchestrated "smooth" billion-dollar exits before (e.g. UCB's asset sales). Per a recent podcast they organize auctions to maximize bids by teasing data snippets and pitting suitors (Sanofi Merck Pfizer Bristol Myers Squibb AstraZeneca) against each other. Rumors peaked November XX 2025 with AstraZeneca flagged as a bidder via Betaville alerts spiking shares 11%. Tactics include phased diligence: initial bids in Q4 2025 final rounds post-earnings (Dec XX 2025) announcement pre-major catalysts to avoid dilution"
X Link 2025-12-06T23:30Z XXX followers, XXX engagements
"$ABVX $ABVX Why we will see a buyout sooner than later read on. Why did the FDA encourage Abivax to skip Phase X and Phase 2a for obefazimod in Crohns disease (CD) The FDA actively encouraged Abivax to go straight into a dose-ranging Phase 2b trial (ENHANCE-CD) without a separate Phase X or small Phase 2a in Crohns because: 1) Extensive existing safety database 1200 patients already treated in UC trials (Phase 2a 2b and ongoing Phase 3) 2) Consistent clean safety profile (no new signals) at the same doses planned for CD (25 mg and XX mg) 3) Same drug same mechanism highly overlapping disease"
X Link 2025-12-08T00:04Z XXX followers, 8663 engagements
"@Taintslapp12283 $ABVX up big after hours. Hope you're locked and loaded. Please don't say you have puts short selling or sold today"
X Link 2025-12-10T00:21Z XXX followers, XXX engagements